Skip to content
lifestyle.entreprenerd.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Ipsen Pharma
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
October 22, 2026
Ipsen appoints Mariette Finet to its Board of Directors
September 18, 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
August 21, 2026
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
July 30, 2026
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
July 29, 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
July 22, 2026
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
July 9, 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
July 1, 2026
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
May 28, 2026
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
May 19, 2026
1
2
Next Page
→